Seminars in Arthritis and Rheumatism
Volume 39, Issue 2 , Pages 116-122, October 2009

Effect of Tumor Necrosis Factor Alpha Inhibition on Bone Density and Turnover Markers in Patients with Rheumatoid Arthritis and Spondyloarthropathy

  • Cheryl Barnabe, MD, FRCPC

      Affiliations

    • Resident, Division of Rheumatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    • Corresponding Author InformationAddress reprint requests to Cheryl Barnabe, MD, FRCPC, University of Calgary, Division of Rheumatology, 1301 3350 Hospital Dr NW, Calgary, Alberta, Canada T2N 2T9
    • ,
  • David A. Hanley, MD, FRCPC

      Affiliations

    • Professor, Departments of Medicine, Community Health Sciences, and Oncology, Division of Endocrinology and Metabolism, University of Calgary, Calgary, Alberta, Canada

published online 01 July 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Cheryl Barnabe has no conflicts of interest to disclose.

 David Hanley claims Amgen as support, clinical trials of Denosumab; and serves on the Canadian advisory board.

PII: S0049-0172(08)00084-X

doi:10.1016/j.semarthrit.2008.04.004

Seminars in Arthritis and Rheumatism
Volume 39, Issue 2 , Pages 116-122, October 2009

Article Tools